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ORIGINAL ARTICLES
A Prospective Randomized Study in 100 Consecutive
Patients Undergoing Major Liver Resection With Versus
Without Ischemic Preconditioning
Pierre-Alain Clavien, MD, PhD,*§ Markus Selzner, MD,*§ Hannes A. Ru¨diger, MD,*§
Rolf Graf, PhD,* Zakiyah Kadry, MD,* Valentin Rousson, PhD,† and Wolfram Jochum, MD‡
Objective: To evaluate the protective effects of ischemic precondi-
tioning in a prospective randomized study involving a large popu-
lation of unselected patients and to identify factors affecting the
protective effects.
Summary Background Data: Ischemic preconditioning is an ef-
fective protective strategy in several animal models. Protection has
also been suggested in a small series of patients undergoing a
hemihepatectomy with 30 minutes of inflow occlusion. Whether
preconditioning confers protection in other types of liver resection
and longer periods of ischemia is unknown. Therefore, we con-
ducted a prospective randomized study to evaluate the impact of
ischemic preconditioning in liver surgery.
Methods: A total of 100 unselected patients undergoing major liver
resection ( bisegmentectomy) under inflow occlusion for at least
30 minutes were randomized during surgery to either receive or not
receive an ischemic preconditioning protocol (10 minutes of ischemia
followed by 10 minutes of reperfusion). Univariate and multivariate
analyses were performed to identify independent factors affecting the
protective effects of ischemic preconditioning. ATP contents in liver
were measured as a possible mechanism of protection.
Results: Both groups (n  50 in each) were comparable regarding
age, gender, duration of inflow occlusion, and resected liver vol-
umes. Postoperative serum transaminase levels were significantly
lower in preconditioned than in control patients (median peak AST
364 U/L vs. 520 U/L, P 0.028; ALT 406 vs. 519 U/L, P 0.049).
Regression multivariate analysis revealed an increased benefit of
ischemic preconditioning in younger patients, in patients with longer
duration of inflow occlusion (up to 60 minutes), and in cases of
lower resected liver volume (50%). Patients with steatosis were
also particularly protected by ischemic preconditioning. ATP con-
tent in liver tissue was preserved by ischemic preconditioning in
young but not older patients.
Conclusions: This study establishes ischemic preconditioning as a
protective strategy against hepatic ischemia in humans. The strategy
is particularly effective in young patients requiring a prolonged
period of inflow occlusion, and in the presence of steatosis, and is
possibly related to preservation of ATP content in liver tissue. Other
strategies are needed in older patients.
(Ann Surg 2003;238: 843–852)
Blood loss and transfusions during liver resection areassociated with unfavorable short- and long-term out-
comes.1–4 Inflow occlusion through clamping of the portal
triad (Pringle maneuver) in combination with a low central
venous pressure is routinely used in many centers to prevent
blood loss during transection of the liver parenchyma. The
Pringle, maneuver, however causes ischemic injury to the
remaining liver with a risk of poor postoperative outcome.2,5
Diseased livers with steatosis or fibrosis poorly tolerate reper-
fusion injury and can develop liver failure even after short
periods of ischemia.6
Intermittent clamping of the portal triad has been used
as an effective strategy to minimize ischemic injury during
liver surgery despite long periods of ischemia.7 The protec-
tive effects of intermittent clamping against ischemic injury
have been demonstrated in several clinical8–10 and experi-
mental studies.11,12 A drawback inherent to intermittent
clamping is the blood loss during each period of reperfusion
and the increased operative time.10 An alternative to inter-
mittent clamping is ischemic preconditioning, in which a
brief period of ischemia and reperfusion is applied prior to the
prolonged ischemic insult. Several studies in rodent models
have shown significant protection from ischemic precondi-
tioning, including increased animal survival after prolonged
periods of hepatic ischemia.13–17 For example, in a study in
mice, we found that ischemic preconditioning was as effec-
tive as intermittent clamping against ischemic injury with up
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to 75 minutes of inflow occlusion.13 We also performed a
pilot nonrandomized study in 24 patients undergoing an
anatomic hemihepatectomy under exactly 30 minutes of in-
flow occlusion.18 Patients pretreated with ischemic precondi-
tioning (10 minutes of ischemia and 10 minutes of reperfu-
sion) had less postoperative hepatic injury as indicated by
lower transaminase levels and endothelial cell injury. Of note
was the observation that patients with a steatotic liver were
particularly protected by the ischemic preconditioning proto-
col. However, a randomized study demonstrating the protec-
tive effects of ischemic preconditioning in an unselected
group of patients is not available.
Therefore, we designed a prospective randomized study
in 100 consecutive patients undergoing major liver resection,
in which the only exclusion criterion was cirrhosis or im-
paired preoperative function. The aim of the study was to
evaluate the protective effects of ischemic preconditioning
with particular attention to identifying factors that may im-
pact on this effect in humans. A secondary aim was to assess
potential mechanisms of protection, such as restoration of
adenosine triphosphate (ATP) in liver tissue after reperfusion.
METHODS
Experimental Design
Between April 1999 and December 2001, 100 consec-
utive patients undergoing major liver resection under contin-
uous inflow occlusion (Pringle maneuver) were randomized
to receive ischemic preconditioning prior to continuous in-
flow occlusion and liver resection. Ischemic preconditioning
was performed through an inflow occlusion (Pringle maneu-
ver) of 10 minutes followed by 10 minutes of reperfusion
prior to the prolonged ischemic insult, as reported previously
18 (Fig. 1). Each patient was operated under the supervision
of the same hepatobiliary surgeon (P.-A.C.). The time of
continuous inflow occlusion was adapted to the need but had
to exceed 30 minutes, as this is the minimal ischemic time
associated with detectable post-reperfusion injury. Cirrhotic
patients and patients receiving additional ablation therapies
(cryosurgery or radiofrequency) were excluded from the
study. Patients requiring total hepatic exclusion, reconstruc-
tion of the cava, or a Roux-en-Y hepaticojejunostomy were
included. No patient dropout occurred after randomization.
Surgical Procedure
The protocol was approved by the ethics committees of
both Duke University Medical Center (Durham, NC), where
the study was initiated, and the University Hospital of Zurich,
where the majority of patients were included. An informed
consent was obtained from each patient prior to surgery. Each
patient was randomized and included in the study in the
operating room after intraoperative ultrasound was performed
using sealed envelopes (50 controls and 50 ischemic precon-
ditioning). After assigning the patient to either control or
preconditioning group, liver resection was performed with
continuous clamping of the portal triad for at least 30 min-
utes. All types of liver resection requiring resection of more
than 2 segments were included in the study. The need for a
Roux-en-Y hepaticojejunostomy, vena cava resection, or
technique of total vascular exclusion was not an exclusion
criteria. Clamping of the portal triad (Pringle maneuver) was
performed with the tourniquet technique using a 4-mm mer-
silene tape. A low central venous pressure (0–5 mm Hg) was
routinely maintained during the transection period to avoid
backflow from the suprahepatic veins. Central venous pres-
sure was kept higher in cases involving total vascular occlu-
sion of the liver, where an additional tourniquet was placed
on the infrahepatic cava and a large vascular clamp on the
suprahepatic cava. Immediately after clamping of the portal
triad, the parenchymal transection was initiated with the
Kelly clamp crushing technique under vascular inflow occlu-
sion. Small vessels were occluded with the bipolar forceps.
Larger vessels or bile ducts were occluded with metallic clips
or ligated with 2–0 silk. Tru cut liver biopsies were obtained
prior to resection and 30 minutes after reperfusion.
Data regarding duration of surgery, intraoperative
blood loss and transfusion, and ICU and hospital stays were
prospectively collected. Each negative intraoperative and
postoperative event was also recorded. The percentage of
resected liver volume was evaluated intraoperatively by a
single surgeon (P.-A.C.) according to the proportion of re-
sected liver parenchyma. The degree of ischemic injury of the
FIGURE 1. Treatment protocol of the preconditioning and the control groups. Preconditioning patients received 10 minutes of
ischemia and 10 minutes of reperfusion (ischemic preconditioning) prior to the prolonged ischemic insult.
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liver was determined by serial postoperative serum bilirubin,
aspartate aminotransferase (AST), and alanine aminotransfer-
ase (ALT) levels measured daily until discharge. Prothrombin
time was also recorded daily. Each biopsy was evaluated by
a pathologist (W.J.) in a blinded fashion to identify underly-
ing disorders such as steatosis, fibrosis, and other types of
injury.
Measurement of ATP
Liver tissue for ATP measurement was collected prior
to ischemia (baseline) and 30 minutes after reperfusion. ATP
in liver tissue was determined by a bioluminescent assay
(ATP Assay kit, Calbiochem). Small pieces of liver (10
mg) were homogenized using a Teflon homogenizer in
HEPES buffer provided in the kit. The proteins were precip-
itated by the addition of one fifth volume of trichloroacetic
acid solution (6%) and of one tenth volume of somatic cell
ATP releasing reagent. The samples were centrifuged at 3000
rpm, 4°C for 15 minutes. The supernatant was removed and
neutralized with 0.1 N NaOH to establish a pH between 7 and
8. For analysis, the samples were diluted 1:25 in HEPES
buffer. Immediately prior to measurements, ATP standards
were prepared (10-6 to 10-12 M). A total of 100 L of
standard or sample was added to a white microplate (Fluro-
nunc Maxisorp) and equilibrated to room temperature, fol-
lowed by the addition of 50 L of freshly dissolved lucif-
erase. Luminescence was measured in a 96-well Perkin Elmer
Bioassay reader. Background luminescence (cells and
HEPES without luciferin-luciferase reagent) was insignifi-
cant. To ensure that luminescence was derived from tissue
ATP, apyrase (U/mL) was added to some test samples, which
resulted in an almost complete reduction of luminescence.
ATP was calculated and expressed as nmol ATP per mg total
protein. For analysis of the data, ATP contents of liver tissue
before surgery were subtracted from those after reperfusion.
Statistical Analysis
The patients were evaluated as an intention-to-treat
analysis. Summary statistics are expressed as median  SD.
The sample size was determined from the following state-
ment: The assumption was made that the difference between
the two groups was such that the probability for a better
outcome for one patient in the preconditioning group versus
the patient in the control group was at least 0.7. Applying the
Mann-Whitney U test to a sample size of n  44 patients per
group will lead to a significant result in at least 90% of the
cases.
The Mann-Whitney test was performed to test whether
the two groups differed with respect to a continuous variable
such as age or AST peak. To test whether the two groups
differed with respect to gender, we performed a Fisher exact
test. We then compared both groups with respect to AST peak
in each of the following 10 subpopulations: men and women,
patients younger than 60 years and older than 60 years,
patients with resected liver volume 50% and 50%, pa-
tients with ischemia time40 minutes and40 minutes, and
patients with degree of steatosis 25% and 25%.
To formally test for the influence of gender, age,
resected liver volume, ischemia time, and degree of steatosis
on the difference of the AST peak between the two groups,
we computed multiple regression models, which included an
interaction between the group and one of the covariates above
as explanatory variable, and with the logarithm of AST peak
as the response. The logarithm was taken to be closer to a
normal distribution and to reduce the influence of possible
outliers. The same issue was also tackled as follows. Patients
of the two groups were matched for age, ischemia time, and
volume. We thus defined 50 “pairs of patients” and we were
able to correlate age, ischemia time, and volume with the
difference in AST peak between the two groups. A Spearman
test was then performed.
RESULTS
Are the Ischemic Preconditioning and the
Control Groups Comparable?
Fifty-seven men and 43 women with a median age of
57 years (range 20–84 years) were included in the study. The
median resected liver volume was 45% (range 20%-80%) of the
total liver volume with a median Pringle time of 37 minutes
(range 30–60 minutes). There was no significant difference
regarding the patient age, gender, ischemia time, resected liver
volume, or degree of steatosis between patients randomized in
the preconditioning versus control group (Table 1).
Forty-three patients were operated for liver metastases
from a colorectal cancer, 16 for hepatocellular carcinoma, 4
for cholangiocellular carcinoma, and 8 patients for various
kinds of metastatic diseases. In 29 patients, liver resection
was performed for benign diseases, such as liver adenoma,
focal nodular hyperplasia, or benign bile duct stricture. The
different diagnoses were distributed homogeneously between
the preconditioning and control groups.
TABLE 1. Patients and Surgical Characteristics of the
Preconditioning and the Control Group
Patient Characteristics Control Preconditioning P
No. 50 50 —
Sex (F:M) 1:1 1:1.3 0.68
Age (yr) 57  14 59  14 0.89
Ischemia time (min) 35  6.8 36  5.9 0.67
Resected volume (%) 40  19.9 57  22.7 0.41
Note: No significant differences were noted between the groups.
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An extended right hemihepatectomy (SIV-VIII) was
performed in 22 patients, while 6 patients underwent an
extended left liver resection (SI-IV). A formal left (SI-IV)
or right (SV-VIII) hemihepatectomy was performed in 22 and
25 patients, respectively. Twenty-five patients received a
segmental resection involving at least 2 segments, including
5 patients with a formal SII-III bisegmentectomy. The type
and number of procedures were comparable between both
groups.
Does Ischemic Preconditioning Affect Blood
Loss, the Need for Transfusion, and Operating
Time?
The overall median operation time was 220 minutes
(range 140–440 minutes) with a median blood loss of 250
mL (range 50–5000 mL). One patient with a history of major
abdominal trauma had a considerable blood loss of 5 L during
surgery. There was no difference between the precondition-
ing and control groups regarding the length of surgery (225
73 minutes vs. 240  92 minutes) or blood loss (250  290
mL vs. 225  325 mL). Only 6 patients in the entire study
received blood transfusion during surgery and were equally
distributed with 3 in the control and 3 in the preconditioning
group, respectively.
Does Ischemic Preconditioning Affect the
Intensive Care and Hospital Stays, and
Postoperative Complications?
No patient death occurred in this series. No difference
was observed between the control and preconditioning group
regarding hospital (median 7 days, range 3–54 days) or
intensive care unit (median 1 day, range 0–16 days) stays.
Four patients (2 in each group) experienced major complica-
tions, including 1 postoperative stroke, 1 temporary enceph-
alopathy requiring ICU care, 1 biloma, and 1 large pleural
effusion requiring drainage. Other more minor complications
included 6 wound infections, 3 urinary tract infections, and 2
cases of urinary retention, resulting in an overall complica-
tion rate of 15%.
Does Preconditioning Prevent Postoperative
Liver Injury?
The degree of ischemia and reperfusion injury of the
liver was assessed by postoperative peak serum AST and
ALT levels. The transaminase peak occurred between 12
hours and the third postoperative day in all cases. In most
patients, AST and ALT levels returned to normal values
within 7 days. Patients treated with ischemic preconditioning
had a significantly lower peak AST value when compared
with the control group (364 vs. 520 U/L, P  0.028) (Fig. 2).
Similarly, peak ALT values were significantly reduced in the
preconditioning group when compared with patients receiv-
ing portal clamping alone (406 vs. 519 U/L, P  0.049). In
contrast, there were no differences between the control and
the preconditioning group regarding postoperative prothrom-
bin times (76%  18% vs. 81%  14%), bilirubin (46  43
mol/L vs. 56  51 mol/L), alkaline phosphatase (124 
80 U/l vs. 174  142 U/L), and creatinine levels (101  70
mol/L vs. 74  14 mol/L).
Which Factors Influence the Effects of
Preconditioning in the Multivariate Analysis?
Univariate and multivariate analyses were performed to
identify factors related to the characteristics of the patients
and surgery affecting the protective effects of precondition-
ing. Two factors were found to be statistically significant in
the multivariate analysis, including age of the patients and the
amount of resected tissue. Age of the patients was found to be
the most significant parameter influencing the effects of
ischemic preconditioning. The protective effects were maxi-
mal in younger patients and decreased with rising age of the
patients (Fig. 3). For example, when compared with the
control group, preconditioning halved postoperative transam-
inase levels in patients younger than 60 years (Fig. 4). This
effect was lost in patients older than 60 years of age with
similar transaminase levels in the preconditioning and the
control groups.
The protective effects of ischemic preconditioning in-
versely correlated with the percentage of resected tissue.
Preconditioning was associated with a more than half reduc-
tion of peak transaminase levels in patients undergoing re-
sections involving 50% of the total liver volume. In con-
trast, the effects of preconditioning was lost in patients
undergoing major tissue loss (50%) (Fig. 5).
Finally, the protective effects of ischemic precondition-
ing were also more apparent in patients with increasing
ischemic times. While only moderate protection of precondi-
tioning was observed in patients with clamping times 40
minutes, patients with longer ischemic times demonstrated
more pronounced protective effects (Fig. 6). Although a 50%
decrease of AST was present in patients with prolonged
FIGURE 2. Peak AST levels of the preconditioning and the
control groups after liver resection. Ischemic preconditioning
resulted in decreased AST levels when compared with the
control (n  50 in each group, P  0.028).
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ischemia times, the value did not reach statistical significance
due to a high standard deviation (P  0.086).
Did the Presence of Steatosis or Fibrosis
Influence the Protective Effects of Ischemic
Preconditioning?
Particular attention was paid to the presence of steatosis
in the baseline biopsy. Although steatosis was not found to be
significant in the multivariate analysis, probably due to the
small sample size (13 patients), a univariate analysis was
performed to assess the effects of preconditioning in this
population of patients. Six patients in the control group and 7
in the ischemic preconditioning group were found to have fat
deposition in25% of the hepatocytes in the baseline biopsy.
In steatotic patients, ischemic preconditioning demon-
strated particularly strong protective effects in terms of post-
operative serum peak AST levels (363 vs. 602 U/L P 
0.049) (Fig. 7). To assess the influence of steatosis on the
protective effects of ischemic preconditioning in the analysis
of the whole study population, a new analysis was performed
excluding patients with steatosis. In this population, including
only patients (n  87) with normal liver, the protective
effects of ischemic preconditioning remained significant
when compared with the control group (AST levels: 364 vs.
471 U/L, P  0.046) (Fig. 7).
Although cirrhosis was an exclusion criterion, 5 pa-
tients in the control group and 4 patients in the precondition-
ing group were found to have mild portal fibrosis on the
FIGURE 4. Ischemic preconditioning in patients younger than
60 years versus patients 60 years of age or older. Precondition-
ing resulted in a significantly reduced AST level in young
patients. In contrast, older patients were not protected by
ischemic preconditioning with similar AST values when com-
pared with the control.
FIGURE 6. Effects of ischemia time on ischemic precondition-
ing. Ischemic preconditioning resulted in a 50% decrease in
AST levels when 40 minutes inflow occlusion was used
during liver resection. If the inflow occlusion were 40 min-
utes, only a moderate decrease of AST levels was achieved by
preconditioning.
FIGURE 3. The impact of age on postoperative transaminase
levels was evaluated in a match pair analysis. Each dot repre-
sents a pair of patients, one without preconditioning (control)
and one from the preconditioning group. Both patients were
matched for age, Pringle time, and resected volume. The
y-axis represents the difference in peak AST levels in each pair
(delta AST  peak-ASTcontrol – peak-ASTpreconditioning). Higher
delta AST values indicate protection from ischemic precondi-
tioning. Younger patients are maximally protected, whereas
patients older than 70 years appear to have negative effects.
FIGURE 5. Ischemic preconditioning was particularly effective
in patients receiving liver resections of 50% liver volume. In
contrast, no statistical difference was detected between the
preconditioning and the control group if 50% liver volume
were resected.
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baseline biopsy. Preconditioning had comparable protective
effects in patients with mild fibrosis as in patients with
normal livers with a significant reduction in postoperative
peak AST levels (279 vs. 362 U/L, P  0.04).
Is the Protective Effect of Preconditioning
Mediated by Intrahepatic ATP Levels?
We evaluated whether preconditioning protects the
liver against ischemic injury by preserving the intrahepatic
contents of ATP. As the effects of ischemic preconditioning
differed between young and older patients (see above), we
hypothesized that ATP contents may account, at least in part,
for this observation. To address this hypothesis, we measured
ATP levels in the baseline biopsy (at the opening of the
abdomen) and the biopsy performed 30 minutes after reper-
fusion in a selected group of patients younger and older than
60 years, with or without preconditioning. Therefore, four
groups were selected, including 5 patients in each group. A
matched-paired study analysis was performed for the young
and old patients, respectively. Patients were matched for
ischemia time, resected volume, and age. Patients younger
than 60 years had a significant decrease in intrahepatic ATP
levels between baseline and post-reperfusion values. In con-
trast, preconditioning was associated with higher ATP levels
after reperfusion in this population (Fig. 8). In older patients,
the results were comparable in the control group, but isch-
emic preconditioning did not correct the loss of ATP but
rather resulted in an additional decrease in ATP levels after
reperfusion (Fig. 8).
DISCUSSION
This prospective randomized study in an unselected
group of patients establishes ischemic preconditioning as a
protective strategy against hepatic ischemia in humans. Ad-
ditionally, the data newly indicate that the protective effects
correlate with the age of the patients and the volume of the
remaining liver left after resection. The study also confirms
previous results suggesting that ischemic preconditioning is
particularly effective in diseased liver such as steatosis.
Finally, the results indicate preservation of ATP contents in
the liver after reperfusion as a protective mechanism of
ischemic preconditioning, and may explain the failure of the
older liver to respond to preconditioning.
In a previous nonrandomized study, we provided the
first evidence that ischemic preconditioning may protect
against ischemic injury to the liver in humans.18 In this initial
study, including 24 patients, all efforts were made to mini-
mize variability. Each patient underwent a standardized ana-
tomic hemihepatectomy under exactly 30 minutes of inflow
exclusion with a low (0–5 mm Hg) central venous pressure.
On an alternative basis, half of the patients received the same
ischemic preconditioning protocol as in the current random-
ized study. The results indicated a significant protection with
50% reduction of the postoperative serum transaminases. The
protection was even stronger among the 7 patients with mild
to moderate steatosis. Additionally, as data from several
animal models21,22 have shown that the initial injury follow-
ing warm ischemia occur in the sinusoidal endothelial cells,
we also investigated endothelial cell injury in the pilot
study.18 Using special staining such as Tunnel assay for
apoptosis and electron microscopy, we found strong protec-
tion from ischemic preconditioning against early sinusoidal
endothelial cell injury. The purpose of the current random-
FIGURE 7. Ischemic preconditioning was particularly effective
in steatotic livers with a 40% decrease of postoperative peak
AST levels. In contrast, a smaller AST reduction was achieved
by preconditioning in nonsteatotic livers when compared with
the control.
FIGURE 8. ATP levels were determined in the liver tissue from
old (60 years) and young (60 years) patients with or
without preconditioning. Patients were matched for age, isch-
emia time, and resected liver volume in the young and old
patient group. The results are expressed as ATP content in the
post-reperfusion biopsy (Rp) minus the baseline biopsy (BL)
per milligram of protein. In the young group, control patients
decreased the intrahepatic ATP levels during ischemia and
reperfusion, while ischemic preconditioning resulted in an
increased intrahepatic ATP content. In the old group, control
patients also decreased the ATP level during ischemia and
reperfusion. Ischemic preconditioning in old patients resulted
in a further decline of post-reperfusion ATP values.
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ized study was to evaluate the effectiveness of ischemic
preconditioning in a large unselected group of patients and to
identify factors affecting the protective effects.
First, considering the entire series, we found statisti-
cally significant protection from ischemic preconditioning in
terms of postoperative AST and ALT levels. These results
highlight the overall important protective effects against
reperfusion injury considering the heterogeneous group of
patients with ischemic times ranging from 30 minutes to 60
minutes, resection volumes from only 20% to as much as
70% of the total liver volume, the use of additional proce-
dures such as hepaticojejunostomy, and patients with or
without hepatic steatosis. The lack of differences regarding
morbidity rates, and the ICU and hospital stays should be
related to the overall low complication rates and early dis-
charge from the ICU and hospital. For example, only 4
patients in this series experienced major complications re-
quiring a significant prolongation of the ICU or hospital stay.
There was also no mortality in this series. However, one can
speculate that with a much larger sample size differences will
be found as postoperative transaminase levels following isch-
emia are the best markers of injury.23
Next, another important aim of the study was to iden-
tify factors affecting the protective effects of ischemic pre-
conditioning. Using a multivariate analysis, we found that age
of the patients was the most significant factor affecting the
effectiveness of ischemic preconditioning. For example, the
protective effect was completely lost in patients older than 60
years while the effects were maximal in young patients. This
is a novel finding with important clinical and scientific
significance. Several mechanisms might account for the dif-
ference in protection between young and older patients. First,
the protective effect of preconditioning might be associated
with the preservation of post-reperfusion ATP levels, as
suggested in animal studies.24,25 We found that continuous
inflow occlusion was associated with a decrease in intra-
hepatic ATP levels in young and old patients. Ischemic
preconditioning prevented the decrease of ATP in young, but
not in older, patients. These results are consistent with ex-
perimental data in young mice showing that ischemic pre-
conditioning prevents the ATP decrease during hepatic isch-
emia.24,25 High post-reperfusion ATP contents might be
important to withstand reperfusion injury. We can speculate
that a high ATP content might enable hepatocytes and sinu-
soidal endothelial cells to survive, while energy depletion
could lead to cell death. Furthermore, apoptosis as the main
form of post-reperfusion cell death requires ATP for the
activation of the apoptotic cascade. This pathway might fail
in the presence of low ATP contents, resulting in an unfa-
vorable necrotic form of cell death.
Furthermore, the tolerance of hepatocytes against isch-
emic injury might be different in young versus older patients.
The short period of ischemia during preconditioning might be
harmless on hepatocytes in young patients and induce pro-
tection, while the same ischemic time may cause significant
injury in the elderly. Another possibility might be that aging
directly affects the protective mechanisms of ischemic pre-
conditioning, which might no longer be active after 60 years
of age. For example, the sublethal oxidative stress triggering
the protective mechanisms of ischemic preconditioning26
might not occur in older patients. Finally, ischemic injury in
young and old patients might be associated with different
mechanisms of reperfusion injury, such as the increased
susceptibility to the apoptotic cascade or dysfunction of
mediators of protection, such as Bcl-2.
The protective effects of preconditioning were more
pronounced with increased ischemic time. In our study, the
lower limit of inflow occlusion was set at 30 minutes because
this is the minimal ischemia time associated with detectable
injury after reperfusion. It is possible that the relatively low
degree of reperfusion injury in livers subjected to ischemic
times 40 minutes, as highlighted in this series by postop-
erative transaminase levels, may have somewhat prevented
the identification of the protective effects of preconditioning.
Of note, in rodent models, we observed only minimal apo-
ptosis after ischemic periods 45 minutes, whereas the
number of apoptotic hepatocytes and sinusoidal endothelial
cells increased dramatically with longer periods of isch-
emia.27 As preconditioning mainly prevents hepatocyte and
sinusoidal cell apoptosis in these models, it can be expected
that the protective effects are mainly apparent when the
ischemic injury is sufficient to induce apoptosis in a large
number of cells.
Another finding was the decreased protective effects in
terms of transaminase levels in patients with larger resection
volume. These results should be considered with caution, as
small remnant liver masses were associated with lower post-
reperfusion serum AST levels than larger residual volumes.
Indeed, matching patients for the same ischemic time, we
found that patients with extended liver resection (70% re-
sected liver volume) had lower postoperative peak AST
levels than patients with smaller resection volumes (70%)
(data not shown). Therefore, this observation is likewise due
to a type 2 error (ie, the inability to detect a significant
difference due to the sample size). Studies in patients with
major liver resection are further warranted, as ischemic pre-
conditioning might be important to avoid postoperative liver
failure and death. The current study did not enable us to
address this issue.
Our previous pilot study in humans also suggested a
higher degree of protection by ischemic preconditioning in
the fatty than in the normal liver. In this study, the protective
effects in patients with fatty deposition in 25% of the
hepatocytes were stronger than in the normal liver. This
finding is of particular clinical relevance as the complication
rate including postoperative liver failure is high in the pres-
Annals of Surgery • Volume 238, Number 6, December 2003 Major Liver Resection
© 2003 Lippincott Williams & Wilkins 849
ence of steatosis in patients undergoing major liver resection.
The strong protective effects of preconditioning in steatotic
livers might be associated with the preservation of ATP
during ischemia. Other mechanisms in the fatty liver can
certainly not be excluded. For example, others have shown
that preconditioning of the steatotic mouse liver results in
improved post-reperfusion microcirculation.28
Whether ischemic preconditioning should be used rou-
tinely during liver surgery performed under inflow occlusion
or whether intermittent clamping should rather be used has
remained unclear. Data in humans comparing both strategies
are not available. In a rodent model, we found that intermit-
tent clamping and ischemic preconditioning confer compara-
ble protective effects against ischemic injury with up to 75
minutes of inflow occlusion.18 For longer periods, intermit-
tent clamping was superior. As almost all liver resections are
performed with a clamping time below 75 minutes, we
believe that ischemic preconditioning should be preferable.
The argument mainly relies on the increased blood loss
observed with intermittent clamping when compared with
continuous inflow occlusion.10 In our series, blood loss was
low with only 6 patients (6%) receiving blood transfusion in
the entire series. Additionally, the succession of several
periods of ischemia and reperfusion may increase the oper-
ating time significantly. In our study, the operating times
were similar between patients with versus without ischemic
preconditioning as the period of ischemic preconditioning
was performed during the preparation of the liver prior to
resection.
CONCLUSION
We present the first prospective randomized study es-
tablishing the protective effects of ischemic preconditioning
during liver resection in humans. We believe that ischemic
preconditioning is now justified in young patients, as the
protective effects were particularly pronounced in this popu-
lation, and in patients with steatosis. We would recommend
the use of intermittent clamping in patients older than 60
years of age as ischemic preconditioning was ineffective, and
in cirrhotic patients, as no data are currently available in this
population. Further studies are warranted in these latter two
groups to better understand the mechanisms of injury and to
design novel protective strategies.
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Discussion
DR. D. JAECK: Congratulations for this very interesting
presentation, which is complementary to your previous ex-
perimental and clinical studies on ischemic preconditioning. I
would like to make two comments and to raise three ques-
tions. First, in the present prospective randomized study, you
have compared ischemic preconditioning to continuous
clamping; it would probably have been more relevant, for
inflow occlusion periods of more than 30 minutes, to choose,
for the control group, an intermittent clamping method. Sec-
ond, as there is a great heterogeneity in your patients regard-
ing age, volume of liver resection, and indication for hepa-
tectomy, it would be interesting to report, for both groups,
your data concerning mean blood loss, complication rate,
hospital stay, ICU stay, etc.
My first question is about other parameters than serum
AST concerning the evaluation of hepatic ischemic injury,
such as postoperative bilirubin level or prothrombin time:
how was the evolution of these markers in subgroups of the
control and ischemic preconditioning groups (eg, in patients
undergoing major hepatic resection) in patients with steatosis
and in older patients? Second, did you use in some cases any
method of outflow occlusion (eg, total vascular exclusion or
selective hepatic vein occlusion), and if yes, which effects did
you observe? Third, in your previous pilot clinical study, you
focused on apoptosis of the sinusoidal endothelial cells and
demonstrated that apoptosis of the sinusoidal lining cells was
reduced by the ischemic preconditioning. Did you analyze
damage of the sinusoidal lining cells in the present study and
can you suspect why the ischemic preconditioning was not
effective for the older patients and less effective in patients
undergoing major hepatic resection (50% or more hepatic
volume resection)? Finally, I would like to congratulate again
the authors for this remarkable study.
DR. P.A. CLAVIEN: Dr. Jaeck, thank you so much for
your kind comments and questions. Regarding your sugges-
tion to use intermittent clamping as the control group, I think
we need first to conclusively compare ischemic precondition-
ing with continuous inflow occlusion, since this is the sim-
plest technique of inflow occlusion. As now we confirm in
this study that ischemic preconditioning is superior, I would
agree that the next step is to compare it with intermittent
clamping. Your first question focuses on parameters of injury.
Serum transaminase levels are the best markers of reperfusion
injury in human studies and correlate well with survival in
animal models. The significant difference in AST levels
between the two groups suggests strong protection consider-
ing the heterogeneity of the entire series, including different
surgeries, resected volumes, and ischemia times. The lack of
significant differences regarding other parameters such as
blood loss, bilirubin, PT, ICU stay, and complication rates is
related to limitations inherent to any human trial. Safety was
our primary priority, and as a result, the complication rates
were low. For example, we had no mortality and no patient
required a reoperation for a complication in this series. Only
6 patients required blood transfusion in the entire series,
which also highlights the protective effects of inflow occlu-
sion against blood loss. Regarding your second question, 4
patients underwent a technique of total vascular exclusion;
thus, no conclusion can been drawn from this small sample
size. We did not use techniques of selective hepatic vein
occlusion in this series. Your third question refers to our
previous study suggesting protection of ischemic precondi-
tioning against sinusoidal endothelial cell injury. We did not
investigate this type of injury in these patients.
DR. T.E. STARZL: This is a very interesting paper and I
have been quite interested in the phenomena that you de-
scribed before and again today. It is slightly counterintuitive,
as has been implied here, but to me the most interesting thing
is the 60-year break between the young and the old patients,
and I was just wondering whether it would be possible to give
us some idea of the numbers below and above 60, because
your mean age of the two groups is almost 60 years; it is 57
something in 1 group and 59 in the other, which would
suggest that the number of young patients must be very small
indeed. Could you tell us how many patients were over 60
and how many were under? (It would be very helpful.)
DR. P.A. CLAVIEN: Dr. Starzl, thank you so much for
this question. The age of patients ranged between 20 and 84
years. In both groups, there were 27 patients below 60 years
and 23 above. Figure 3 seems indeed to indicate that the
younger the patient, the stronger the effect of ischemic
preconditioning.
DR. A.M.M. EGGERMONT: You have a very nice overall
data set, which is going to lead to further biologic research
regarding this age question. Nevertheless, we all wrestle with
the same question, as to how you got the number 60.
Can you tell me whether the P value shown and
whether the statement that the P values are significant have
been corrected for multiple analyses? I ask this because
obviously 60 was not predefined; therefore, it was only by a
postanalysis that you came to the conclusion that 60 was the
cutoff value.
DR. P.A. CLAVIEN: Professor Eggermont, thank you for
pointing out the caution needed in interpreting subgroup
analysis in such a data set. This is the reason we look at the
effects of age from different angles to convince ourselves that
the finding is significant and may have an impact on thera-
peutic strategies. Both the raw data and various statistical
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analyses indicated a central role of age on the effects of
ischemic preconditioning. Since then, we went back to the
laboratory, and in a mouse model of ischemic injury to the
liver, we found also that age of animals has an strong impact
on the protective effects of preconditioning. We are now
looking at the underlying mechanisms. I also agree with you
that we need to be careful about our suggested cutoff of 60
years. The data in Figure 3 indicate that ischemic precondi-
tioning appears to be deleterious in patients older than 70
years of age, and for wise practical advise we suggest not
using ischemic preconditioning in patients older than 60 years
of age at this point.
DR. M. MAKUUCHI: Thank you for your beautiful pre-
sentation. In the introduction, you said that when you perform
intermittent clamping, you had a large amount of bleeding
during reperfusion. So, you did not apply the method. But
when we perform living donor liver transplantation, the
intermittent Pringle maneuver is used routinely in donor
hepatectomy. There is no bleeding after declamping. It is
mainly depending whether hemostasis of the transecting sur-
face of the removing side of the liver is undergone or not. If
hemostasis is not performed on the resecting side, it results in
a massive bleeding during declamping. Massive bleeding is
depending on the divided portal pedicle, but the hepatic vein
is not the cause. We perform a 10-minute occlusion as
preconditioning and followed by 5 minutes of perfusion and
then after a 15-minute occlusion is repeated. In hemihepatic
or selective inflow occlusion, we perform 30-minute occlu-
sion. There is no difference of the transaminase levels after
liver resection.
I would like to ask you whether you perform precon-
ditioning and intermittent inflow occlusion in living donor
liver transplantation settling. We perform the intermittent
Pringle maneuver with preconditioning in liver donor hepa-
tectomy. The posttransplantation ALT value was significantly
lower in the intermittent Pringle group. I believe that inter-
mittent inflow occlusion is very safe even in living donor
hepatectomy for liver transplantation.
DR. P.A. CLAVIEN: Thank you very much Prof. Makuu-
chi for your comments. We did not study intermittent clamp-
ing here, but this strategy presents the risk in many hands of
bleeding during each reperfusion period. For example, Bel-
ghiti et al showed in a paper published in Annals of Surgery
(1999) that bleeding was significantly higher during paren-
chymal dissection when intermittent clamping was used,
when compared with continuous occlusion. As Professor
Jaeck suggested, I believe a comparison between ischemic
preconditioning and intermittent clamping would be very
timely. Regarding your second point, we have not used or
studied ischemic preconditioning in the setting of living
related transplantation or cold ischemia. Finally, I agree with
your last comment that the best strategy might be a protocol
between ischemic preconditioning and intermittent clamping.
DR. K.G. TRANBERG: We have rarely used the Pringle
maneuver in the last years. Still, we have a decent amount of
bleeding and rarely have to transfuse the patients. Another
reason for having a restrained attitude against intermittent
inflow occlusion is that there is some experimental and also
clinical evidence that this might detach cells from the periph-
ery of the liver tumor.
Maybe it is a good idea to try intermittent inflow
occlusion, or at least to use it only when really needed, from
an oncologic point of view.
DR. P.A. CLAVIEN: Here we are dealing with beliefs
rather than facts. Whether ischemia and reperfusion injury
promotes tumor dissemination remains speculative. Maybe
this is the opposite, as this type of injury is associated with
the release of anti-tumoral cytokines such as TNF. I per-
sonally enjoy performing my major liver resection under
inflow occlusion and low central venous pressure. As seen in
this series, with this strategy blood loss is low and compli-
cations are rare. Dr. Makuuchi seems to like intermittent
clamping even for his living related resection and has excel-
lent results. There is no doubt that the same can be achieved
without occlusion, as you do routinely, but with the need for
a prolonged period of dissection of the parenchyma. We have
the same experience with living related hepatectomy. These
differences in practice suggest that we need additional ran-
domized studies to know the truth.
DR. P.J. FRIEND: ATP is a sensitive marker of paren-
chymal injury, but it does not look particularly at other cells.
I wondered if you looked at other biochemical markers; of
course, there is a range of possiblities.
DR. P.A. CLAVIEN: No we did not look at specific cells
or mechanisms of injury in this series. ATP was assessed
because of the recent available data in animal models sug-
gesting that ischemic preconditioning mainly acts through
preservation or rapid restoration of ATP after reperfusion.
This clinical study is consistent with this finding as ATP was
well preserved by ischemic preconditioning in the protected
patients (ie, the younger patients) but not in those without a
protective effect. This clinical study, as all those related to
translational research, has generated further important ques-
tions and a need to go back to bench studies.
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